UPS delivers 16% revenue growth but shares price in future downside
Ibstock reports decline in revenue, shares fall
Boeing to cut 20% total workforce
GSK and Sanofi sign Statement of Intent to provide 200m COVID vaccines
Once necessary approvals are gained, both companies say they will make their adjuvanted recombinant protein-based COVID-19 vaccine available to the COVAX Facility, to contribute towards its goal of “[reaching] those in need, whoever they are and wherever they live”.
Speaking on the companies’ commitment, Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said:
“To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control. This moment also reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”
Roger Connor, President of GSK Vaccines added:
“Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world. We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible – this has the potential to be a significant contribution to the global fight against COVID-19.”
Having initiated the first of two phases of its trials on September 3, with 440 participants enrolled, GSK stated that it expects first results in early December 2020. It said these results being secured would be ‘pivotal’ to support the initiation of a Phase 3 study before the end of the year. Should the data prove sufficient for licensure application, GSK said it will request regulatory approval during the first half of 2021. In parallel, GSK said that it and Sanofi had been scaling up manufacturing of the antigen and adjuvant respectively. The company adds that the use of an adjuvant technology is particularly important in a pandemic situation, given that it may reduce the amount of vaccine protein required per dose. It continued, saying that it does not expect profit to be made from the COVID vaccine during the pandemic phase, and said it will invest any short-term profit back into COVID-related research and long-term vaccine preparedness.Tribal Group hikes profit expectations, shares rise
Shoe Zone shares down as group admits to “challenging” year
FTSE 100 hits six-month low
“The DAX and CAC, which have spent the week trading off the title of worst hit major index, both shed 3% after the bell. That leaves the German bourse clinging on above 11,700 – just – and at its lowest level in close to 5-months. The French index echoed those lows, as it fell the wrong side of 4600.
“As it has done for much of the week, the FTSE managed to keep its losses at the lower end of the day’s declines. Not that that meant much – it still translated to a 2% drop, forcing it to a 6 and a half month nadir of 5625,” he added.
